Abstract
Purpose
As clinical studies have correlated RANK expression levels with survival in breast cancer, and that RANK signaling is dependent on its cognate ligand RANKL, we hypothesized that dual protein expression further stratifies the poor outcome in TNBC.
Methods
RANK mRNA and protein expression was evaluated in TNBC using genomic databases, cell lines and in a tissue microarray of curated primary tumor samples derived from 87 patients with TNBC. RANK expression was evaluated either by Mann–Whitney U test on log-normalized gene expression data or by Student’s t test on FACS data. Analysis of RANK and RANKL immunostaining was calculated by H-score, and correlations to clinical factors performed using χ 2 or Fisher’s exact test. Associations with RFS and OS were assessed using univariate and multivariate Cox proportional hazard models. Survival estimates were generated using the Kaplan–Meier method.
Results
In three distinct datasets spanning 684 samples, RANK mRNA expression was higher in primary tumors derived from TNBC patients than from those with other molecular subtypes (P < 0.01). Cell surface-localized RANK protein was consistently higher in TNBC cell lines (P = 0.037). In clinical samples, TNBC patients that expressed both RANK and RANKL proteins had significantly worse RFS (P = 0.0032) and OS (P = 0.004) than patients with RANK-positive, RANKL-negative tumors. RANKL was an independent, poor prognostic factor for RFS (P = 0.04) and OS (P = 0.01) in multivariate analysis in samples that expressed both RANK and RANKL.
Conclusions
RANK and RANKL co-expression is associated with poor RFS and OS in patients with TNBC.
Similar content being viewed by others
Abbreviations
- ER:
-
Estrogen receptor
- FACS:
-
Fluorescence-activated cell sorting
- HER2:
-
Human epidermal growth factor receptor 2
- OS:
-
Overall survival
- PR:
-
Progesterone receptor
- RANK:
-
Receptor activator of nuclear factor kappa B
- RANKL:
-
RANK ligand
- RFS:
-
Relapse-free survival
- TNBC:
-
Triple-negative breast cancer
- TMA:
-
Tissue microarray
References
Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N (2009) Triple-negative breast cancer–current status and future directions. Ann Oncol 20(12):1913–1927. doi:10.1093/annonc/mdp492
Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S (2012) Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol 23(9):2223–2234. doi:10.1093/annonc/mds067
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434. doi:10.1158/1078-0432.CCR-06-3045
Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115(2):423–428. doi:10.1007/s10549-008-0086-2
Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320):103–107. doi:10.1038/nature09495
Dougall WC (2012) Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18(2):326–335. doi:10.1158/1078-0432.CCR-10-2507
Walsh MC, Choi Y (2014) Biology of the RANKL-RANK-OPG System in immunity, bone, and beyond. Front Immunol 5:511. doi:10.3389/fimmu.2014.00511
Inoue J (1997) The TRAF family protein-mediated B cell proliferation signal and the mechanism of LMP1-induced B cell transformation. Nihon Rinsho 55(2):299–304
Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299):798–802. doi:10.1038/nature09027
Azim HA Jr, Peccatori FA, Brohee S, Branstetter D, Loi S, Viale G, Piccart M, Dougall WC, Pruneri G, Sotiriou C (2015) RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res 17:24. doi:10.1186/s13058-015-0538-7
Tang ZN, Zhang F, Tang P, Qi XW, Jiang J (2011) RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation. Oncol Rep 26(5):1243–1250. doi:10.3892/or.2011.1368
Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R (2010) Progesterone induces adult mammary stem cell expansion. Nature 465(7299):803–807. doi:10.1038/nature09091
Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98–102. doi:10.1038/nature09387
Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, Climent F, Soler MT, Munoz P, Vinals F, Tometsko M, Branstetter D, Dougall WC, Gonzalez-Suarez E (2012) RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 72(11):2879–2888. doi:10.1158/0008-5472.CAN-12-0044
Blake ML, Tometsko M, Miller R, Jones JC, Dougall WC (2014) RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metas 31(2):233–245. doi:10.1007/s10585-013-9624-3
Pfitzner BM, Branstetter D, Loibl S, Denkert C, Lederer B, Schmitt WD, Dombrowski F, Werner M, Rudiger T, Dougall WC, von Minckwitz G (2014) RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat 145(2):307–315. doi:10.1007/s10549-014-2955-1
Hein A, Bayer CM, Schrauder MG, Haberle L, Heusinger K, Strick R, Ruebner M, Lux MP, Renner SP, Schulz-Wendtland R, Ekici AB, Hartmann A, Beckmann MW, Fasching PA (2014) Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients. Biomed Res Int 2014:842452. doi:10.1155/2014/842452
Park HS, Lee A, Chae BJ, Bae JS, Song BJ, Jung SS (2014) Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. J Surg Oncol 110(7):807–812. doi:10.1002/jso.23737
Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu J, Hou K, Yang X, Liu Y, Qu X (2012) Receptor activator for nuclear factor kappa B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis. J Clin Pathol 65(1):36–40. doi:10.1136/jclinpath-2011-200312
Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM (2013) Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13(5):378–384. doi:10.1016/j.clbc.2013.05.001
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.1200/JCO.2009.25.6529
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical O, College of American P (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/JCO.2013.50.9984
Wood CE, Branstetter D, Jacob AP, Cline JM, Register TC, Rohrbach K, Huang LY, Borgerink H, Dougall WC (2013) Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res 15(4):62. doi:10.1186/bcr3456
Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I (2012) Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 18(16):4415–4424. doi:10.1158/1078-0432.CCR-12-0578
McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109(8):716–721
Hosmer DW Jr, Lemeshow S (2008) Applied survival analysis: regression modeling of time to event data, 2nd edn. Wiley, New York
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. doi:10.1172/JCI45014
Zheng Y, Chow SO, Boernert K, Basel D, Mikuscheva A, Kim S, Fong-Yee C, Trivedi T, Buttgereit F, Sutherland RL, Dunstan CR, Zhou H, Seibel MJ (2014) Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways. J Bone Miner Res 29(9):1938–1949. doi:10.1002/jbmr.2231
Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R (2012) Bench to bedside: elucidation of the OPG-RANK–RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11(5):401–419. doi:10.1038/nrd3705
Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337–342. doi:10.1038/nature01658
Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metas 25(2):119–129. doi:10.1007/s10585-007-9127-1
Holland PM, Miller R, Jones J, Douangpanya H, Piasecki J, Roudier M, Dougall WC (2010) Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther 9(7):539–550
Yoldi G, Pellegrini P, Trinidad EM, Cordero A, Gomez-Miragaya J, Serra-Musach J, Dougall WC, Munoz P, Pujana MA, Planelles L, Gonzalez-Suarez E (2016) RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation. Cancer Res 76(19):5857–5869. doi:10.1158/0008-5472.CAN-15-2745
Acknowledgements
We thank Stephanie Deming for providing editorial support on behalf of Scientific Publications at MD Anderson Cancer Center, and Albert Rhee for providing medical writing support on behalf of Amgen, Inc.
Author’s contribution
Amgen, Inc. funded the study and supported the authors in the development of the study design, and in the collection, analysis, and interpretation of data. MER, TF, DB, HM, BLE, WCD, and NU contributed to the study conception and design; MER, TF, DB, BLE, SK, XW, JR, WW, GH, DT, WCD, and NU contributed to the collection, and analysis of data; MER, TF, DB, BLE, HM, BJE, SK, XW, JMR, WAW, GNH, DT, WCD, and NTU contributed to the interpretation of the data and development of the manuscript. Medical writing support was provided by Amgen, Inc. The decision to submit was taken jointly by all authors and Amgen, Inc. All authors read and approved the final manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Funding
Funding support for this study was provided by Amgen, Inc. Technical support for generation of flow cytometry data was provided by The University of Texas MD Anderson Cancer Center Flow Cytometry and Cellular Imaging Core Facility, funded by the National Cancer Institute Cancer Support Grant P30CA16672.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
Author NU is principal investigator of the above-mentioned study of denosumab (NCT01952054), which is supported by Amgen, Inc. Authors WCD and DB are former employees and shareholders of Amgen, Inc. Authors MER, TF, SK, HM, XW, JMR, WAW, BJE, GNH, DT, BLE declare no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed consent
This study adhered to ethical guidelines at MD Anderson Cancer Center and the IRB study protocol (LAB05-0530).
Rights and permissions
About this article
Cite this article
Reyes, M.E., Fujii, T., Branstetter, D. et al. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat 164, 57–67 (2017). https://doi.org/10.1007/s10549-017-4233-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-017-4233-5